Expired CME Article
Prevention and Management of Antibacterial Resistance for Primary Care Patients with Respiratory Tract Infections
Abstract
This review examines the problem of increasing antibacterial resistance among the pathogens commonly associated with community-acquired respiratory tract infections, particularly Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The increases in morbidity, mortality, and treatment cost associated with increased resistance to available antibiotics are challenging prescribers to find more effective therapeutic strategies. A MEDLINE search of the literature from 1966 to the present was performed to seek data relevant to the issue of resistance, especially the negative effects on patient outcomes and costs of therapy. Several observations and conclusions emerged. Data are lacking on local resistance patterns, broad-spectrum agents are overprescribed when narrower-spectrum choices would be more appropriate, a need exists for educational programs to encourage restricting drug use and changing prescribing habits, and there is a need for new antibiotic choices. The best antibiotic options are agents with a tailored spectrum of activity that are targeted at particular respiratory tract pathogens and have low potential to select for resistant organisms.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Armstrong GL, Pinner RW. Outpatient visits for infectious diseases in the United States, 1980 through 1996. Arch Intern Med 1999; 159: 2531–2536.
2. Jacobs MR. Emergence of antibiotic resistance in upper and lower respiratory tract infections. Am J Manag Care 1999; 5 (11 Suppl): S651–S661.
3. Cunha BA. Antibiotic resistance. Med Clin North Am 2000; 84: 1407–1429.
4. File TM Jr. Overview of resistance in the 1990s. Chest 1999; 115 (3 Suppl): 3S–8S.
5. Jones RN. The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory-tract infections. Am J Health Syst Pharm 1999; 56 (Suppl 3): S4–S11.
6. Hand WL. Current challenges in antibiotic resistance. Adolesc Med 2000; 11: 427–438.
7. Whitney CG, Parley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917–1924.
Davies JE. Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba Found Symp 1997; 207: 15–35.
9. Patterson JE. Antibiotic utilization: Is there an effect on antimicrobial resistance? Chest 2001; 119 (2 Suppl): 426S–430S.
10. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584–599.
11. Steinberg I. Clinical choices of antibiotics: Judging judicious use. Am J Manag Care 2000; 6 (23 Suppl): S1178–S1188.
12. Leclercq R. Safeguarding future antimicrobial options: Strategies to minimize resistance. Clin Microbiol Infect 2001; 7: 18–23.
13. Lister PD. Emerging resistance problems among respiratory tract pathogens. Am J Manag Care 2000; 6 (8 Suppl): S409–S418.
14. Forward KR. The epidemiology of penicillin resistance in Streptococcus pneumoniae. Semin Respir Infect 1999; 14: 243–254.
15. Collignon PJ, Turnidge JD. Antibiotic resistance in Streptococcus pneumoniae. Med J Aust 2000; 173 (Suppl): S58–S64.
16. Ball P. Therapy for pneumococcal infection at the millennium: Doubts and certainties. Am J Med 1999; 107: 77S–85S.
17. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208–1213.
18. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997–1998. Emerg Infect Dis 1999; 5: 757–765.
19. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother 2001; 45: 1721–1729.
20. Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens: A global perspective. Semin Respir Infect 2000; 15: 195–207.
21. Goldstein FW, Acar JF. Epidemiology of antibiotic resistance in Haemophilus influenzae. Microb Drug Resist 1995; 1: 131–135.
22. Brueggemann AB, Doern GV. Resistance among Streptococcus pneumoniae: Patterns, mechanisms, interpreting the breakpoints. Am J Manag Care 2000; 6 (23 Suppl): S1189–S1196.
23. Witte W. Antibiotic resistance in Gram-positive bacteria: Epidemiological aspects. J Antimicrob Chemother 1999; 44 (Suppl A): 1–9.
24. Cassell GH, Mekalanos I. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA 2001; 285: 601–605.
25. Wang EE, Kellner JD, Arnold S. Antibiotic-resistant Streptococcus pneumoniae: Implications for medical practice. Can Fam Physician 1998; 44: 1881–1888.
26. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A 1999; 96: 1152–1156.
27. Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998; 279: 875–877.
28. Bauchner H, Pelton SI, Klein JO. Parents, physicians, and antibiotic use. Pediatrics 1999; 103: 395–401.
29. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43: 459–465.
30. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians. JAMA 1995; 273: 214–219.
31. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001; 29 (4 Suppl): N114–N120.
32. Kollef MH. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 2001; 29 (4 Suppl): N135–N142.
33. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–229.
34. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin Infect Dis 1999; 29: 321–327.
35. Goldstein FW, Garau J. Resistant pneumococci: A renewed threat in respiratory infections. Scand J Infect Dis Suppl 1994; 93: 55–62.
36. Dagan R, Abramson O, Leibovitz E, Lang R, Goshen S, Greenberg D, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996; 15: 980–985.
37. Dagan R, Abramson O, Leibovitz E, Greenberg D, Lang R, Goshen S, et al. Bacteriologic response to oral cephalosporins: Are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997; 176: 1253–1259.
38. Liu HH. Antibiotic resistance in bacteria: A current and future problem. Adv Exp Med Biol 1999; 455: 387–396.
39. Eandi M, Zara GP. Economic impact of resistance in the community. Int J Clin Pract Suppl 1998; 95: 27–38.
40. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (2 Suppl): 43S–52S.
41. MacFarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993; 341: 511–514.
42. Yates RR. New intervention strategies for reducing antibiotic resistance. Chest 1999; 115 (3 Suppl): 24S–27S.
43. Smith DW. Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy 1999; 19: 129S–132S.
44. Dickerson LM, Mainous AG III, Carek PJ. The pharmacist's role in promoting optimal antimicrobial use. Pharmacotherapy 2000; 20: 711–723.
45. Gonzales R, Steiner JF, Lum A, Barrett PH Jr. Decreasing antibiotic use in ambulatory practice: Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999; 281: 1512–1519.
46. Zwar N, Wolk J, Gordon J, Sanson-Fisher R, Kehoe L. Influencing antibiotic prescribing in general practice: A trial of prescriber feedback and management guidelines. Fam Pract 1999; 16: 495–500.
47. McNulty CA, Kane A, Foy CJ, Sykes J, Saunders P, Cartwright KA. Primary care workshops can reduce and rationalize antibiotic prescribing. J Antimicrob Chemother 2000; 46: 493–499.
48. Dowell S, Butler JC, Giebink GC, Jacobs MR, Jernigan D, Musher DM, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: A report form the Drug-resistantStreptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18: 1–9.
49. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399–1408.
50. Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999; 29: 462–463.
51. Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: Background, specific aims, and methods. Ann Intern Med 2001; 134: 479–486.
52. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia. Clin Infect Dis 2000; 31: 347–382.
53. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–1754.
54. Plouffe JF. Emerging therapies for serious gram-positive bacterial infections: A focus on linezolid. Clin Infect Dis 2000; 31 (Suppl 4): S144–S149.
55. Bain KT, Wittbrodt ET. Linezolid for the treatment of resistant Gram-positive cocci. Ann Pharmacother 2001; 35: 566–575.
56. Gleckman R. What do the new antimicrobials offer? Postgrad Med 2001; 109: 1–7.
57. Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 2001; 21: 35–59.
58. Talan DA. Clinical perspectives on new antimicrobials: Focus on fluoroquinolones. Clin Infect Dis 2001; 32 (Suppl 1): S64–S71.
59. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones. J Antimicrob Chemother 2000; 45: 583–590.
60. Delgado G Jr, Neuhauser MM, Bearden DT, Danziger LH. Quinupristin-dalfopristin: An overview. Pharmacotherapy 2000; 20: 1469–1485.
61. Bearden DT, Neuhauser MM, Garey KW. Telithromycin: An oral ketolide for respiratory infections. Pharmacotherapy 2001; 21: 1204–1222.
62. Depardieu F, Courvalin P. Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 319–323.
63. Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001; 45: 1–12.
64. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 414–417.
65. Felmingham D. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect 2001; 7: 2–10.
66. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207–208(letter).
67. Pai MP, Gonzales RD, Petrolati JM, et al. Risk factors associated with the development of enterococcal resistance to linezolid. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Dec 16–19, 2001 (abstract 1194).
68. Stratton C, Barry A, Yee YC. In vitro activity of telithromycin against clinical isolates ofStreptococcus pneumoniae collected from medical centers across the United States during the winter of 2000/2001. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001 (abstract 1018).
69. Goldsmith CE, Moore JE, Murphy PG, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J Antimicrob Chemother 1998; 41: 420–421(letter).
70. Descheemaeker P, Chapeele S, Lammens C, Hauchecorne M, Wijdooghe M, Vandamme P, et al. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother 2000; 45: 167–173.
71. Hoban D, Brown S, Harding I. Telithromycin is highly active against erythromycin-susceptible and -resistant isolates of Streptococcus pyogenes collected in the United States during the winter of 2000–2001. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001 (abstract 1017).
72. Larsen EL. APIC guidelines for hand washing and hand antisepsis in health-care settings. Am J Infect Control 1995; 23: 251–269.
73. Garner JS, Favero MS. CDC guidelines for handwashing and hospital environmental control, 1985. Infect Control 1986; 7: 231–235.
74. U.S. Food and Drug Administration. Topical antimicrobial drug products for over-the-counter human use. 21 CFR ch I, pt 333 (Rev. April 1, 2002). Available at:http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=333. Accessed April 2, 2003.
75. Burns IT, Zimmerman RK. Haemophilus influenzae type B disease, vaccines, and care of exposed individuals. J Fam Pract 2000; 49 (9 Suppl): S7–S14.
76. Ortqvist A. Pneumococcal vaccination: Current and future issues. Eur Respir J 2001; 18: 184–195.
